These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36957976)

  • 1. Role of the Microbiome in Immunotherapy of Melanoma.
    Jiminez V; Yusuf N
    Cancer J; 2023 Mar-Apr 01; 29(2):70-74. PubMed ID: 36957976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The gut microbiome and melanoma: A review.
    Makaranka S; Scutt F; Frixou M; Wensley KE; Sharma R; Greenhowe J
    Exp Dermatol; 2022 Sep; 31(9):1292-1301. PubMed ID: 35793428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of gut microbiome on immunotherapy efficacy in melanoma.
    Bibbò S; Ianiro G; Giambò F; Settanni CR; Cammarota G; Gasbarrini A
    Hum Vaccin Immunother; 2022 May; 18(3):1926759. PubMed ID: 34190675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Microbiome in Advanced Melanoma: Where Are We Now?
    Fortman DD; Hurd D; Davar D
    Curr Oncol Rep; 2023 Sep; 25(9):997-1016. PubMed ID: 37269504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cure from within? a review of the microbiome and diet in melanoma.
    Kumar P; Brazel D; DeRogatis J; Valerin JBG; Whiteson K; Chow WA; Tinoco R; Moyers JT
    Cancer Metastasis Rev; 2022 Jun; 41(2):261-280. PubMed ID: 35474500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbial Influences on Immune Checkpoint Inhibitor Response in Melanoma: The Interplay between Skin and Gut Microbiota.
    Bouferraa Y; Fares C; Bou Zerdan M; Boyce Kennedy L
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients.
    Natarelli N; Aflatooni S; Boby A; Krenitsky A; Grichnik J
    J Drugs Dermatol; 2024 Feb; 23(2):78-84. PubMed ID: 38306142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma and microbiota: Current understanding and future directions.
    Routy B; Jackson T; Mählmann L; Baumgartner CK; Blaser M; Byrd A; Corvaia N; Couts K; Davar D; Derosa L; Hang HC; Hospers G; Isaksen M; Kroemer G; Malard F; McCoy KD; Meisel M; Pal S; Ronai Z; Segal E; Sepich-Poore GD; Shaikh F; Sweis RF; Trinchieri G; van den Brink M; Weersma RK; Whiteson K; Zhao L; McQuade J; Zarour H; Zitvogel L
    Cancer Cell; 2024 Jan; 42(1):16-34. PubMed ID: 38157864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
    Lau HCH; Sung JJ; Yu J
    Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33435800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DeepGeni: deep generalized interpretable autoencoder elucidates gut microbiota for better cancer immunotherapy.
    Oh M; Zhang L
    Sci Rep; 2023 Mar; 13(1):4599. PubMed ID: 36944780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.
    Guardamagna M; Berciano-Guerrero MA; Villaescusa-González B; Perez-Ruiz E; Oliver J; Lavado-Valenzuela R; Rueda-Dominguez A; Barragán I; Queipo-Ortuño MI
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.
    Matson V; Chervin CS; Gajewski TF
    Gastroenterology; 2021 Jan; 160(2):600-613. PubMed ID: 33253684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma.
    Limeta A; Ji B; Levin M; Gatto F; Nielsen J
    JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33268597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Microbiome and Liver Cancer.
    Myojin Y; Greten TF
    Cancer J; 2023 Mar-Apr 01; 29(2):57-60. PubMed ID: 36957974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
    Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiome in modulating immune checkpoint inhibitors.
    Li X; Zhang S; Guo G; Han J; Yu J
    EBioMedicine; 2022 Aug; 82():104163. PubMed ID: 35841869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review.
    Nagasaka M; Sexton R; Alhasan R; Rahman S; Azmi AS; Sukari A
    Crit Rev Oncol Hematol; 2020 Jan; 145():102841. PubMed ID: 31884204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unbiased Microbiome and Metabolomic Profiling of Fecal Samples from Patients with Melanoma.
    Bui A; Choi Y; Frankel AE; Koh AY
    Methods Mol Biol; 2021; 2265():461-474. PubMed ID: 33704734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
    Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
    Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
    Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
    Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.